Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Vitamin-Like supplement ward off Alzheimer's in High-Risk individuals?

NCT ID NCT05880849

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study tested whether taking choline, a dietary supplement, for 6 months could improve fat metabolism in the brain of people with the APOE4 gene, which raises Alzheimer's risk. Fifteen participants aged 55-80 took choline capsules twice daily. The main goal was to check safety and see if choline changes certain fat-related markers in spinal fluid. This early trial focuses on biological effects, not on preventing or treating Alzheimer's symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
choline (a dietary supplement)
What this could lead to
If it works, this could point toward a simple dietary supplement to help delay or prevent Alzheimer's in people with the APOE4 gene.
What could go wrong
This is a very early, small phase 1 trial with only 15 people. It mainly checks safety and biological changes, not whether choline actually prevents Alzheimer's. The results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Started

Jun 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Has signed an informed consent form before any assessment is performed as part of the study. 2. Be male or female between 55 and 80 years old. 3. Be able to understand the nature of the study and have the opportunity to have all questions answered. 4. Has tested positive for at least one copy of ApoE4. 5. Has an MMSE score of 24 or greater. (can be based on documented result obtained within the previous 3 months). 6. Is in the opinion of the Investigator, in good general medical health based upon medical history, physical examination, laboratory tests, vital signs and EKG. 7. Has normal levels of Homocysteine in blood tests. A normal blood level is between 5 to 15 micromoles (mcmol/L) 8. Completes the dietary interview with dietician. 9. Females must be considered post-menopausal or not of child bearing potential. Exclusion Criteria: 1. Current medical or neurological condition that might impact cognition or performance on cognitive assessments. (e.g. TBI, Parkinson's disease, multiple sclerosis, etc.) 2. Inability or unwillingness of patient to undergo neuropsychological testing. 3. Advanced, severe progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the participant at special risk. (e.g. significant cardiac disease, severe renal impairment, severe hepatic impairment etc.) 4. History of malignancy of any organ system, treated or untreated, within the past 60 months. 5. Inability or unwillingness to undergo Lumbar Punctures. 6. High dietary choline intake (more than 450mg) as determined by dietician 7. Any condition, which in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Texas Health Science Center at Houston (UTHealth)

    Houston, Texas, 77054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.